|
2025-01-17 |
2025-01-16 |
S
Sale
|
Nighan Warren JR
SVP Quality and Regulatory
Officer
|
4,060
-8.8%
12.31
USD 49,979
|
4,060
-8.8%
|
12.31
|
USD 49,979
|
|
|
2024-10-10 |
2024-10-10 |
B
Purchase
|
Nighan Warren JR
SVP Quality and Regulatory
Officer
|
100
+0.2%
6.08
USD 608
|
100
+0.2%
|
6.08
|
USD 608
|
|
|
2024-10-08 |
2024-10-08 |
B
Purchase
|
Trowbridge Stephen A
EVP and CFO
Officer
|
1,700
+1.0%
5.86
USD 9,962
|
1,700
+1.0%
|
5.86
|
USD 9,962
|
|
|
2024-10-10 |
2024-10-07 |
B
Purchase
|
Nighan Warren JR
SVP Quality and Regulatory
Officer
|
768
+1.7%
6.09
USD 4,677
|
768
+1.7%
|
6.09
|
USD 4,677
|
|
|
2024-10-08 |
2024-10-07 |
B
Purchase
|
Clemmer James C
President and CEO
Executive Director
|
20,000
+3.0%
6.03
USD 120,600
|
20,000
+3.0%
|
6.03
|
USD 120,600
|
|
|
2024-04-08 |
2024-04-08 |
B
Purchase
|
Clemmer James C
President and CEO
Executive Director
|
10,000
+1.9%
6.70
USD 67,000
|
10,000
+1.9%
|
6.70
|
USD 67,000
|
|
|
2023-02-01 |
2023-01-31 |
S
Sale
|
Helsel Dave
SVP Global Operations and R&D
Officer
|
4,633
-19.4%
12.95
USD 59,997
|
4,633
-19.4%
|
12.95
|
USD 59,997
|
|
|
2022-10-12 |
2022-10-12 |
B
Purchase
|
Trowbridge Stephen A
EVP and CFO
Officer
|
1,083
+1.2%
13.82
USD 14,967
|
1,083
+1.2%
|
13.82
|
USD 14,967
|
|
|
2022-10-11 |
2022-10-10 |
B
Purchase
|
Clemmer James C
President and CEO
Executive Director
|
10,000
+2.3%
15.00
USD 150,000
|
10,000
+2.3%
|
15.00
|
USD 150,000
|
|
|
2022-08-01 |
2022-07-29 |
S
Sale
|
Helsel Dave
SVP Global Operations and R&D
Officer
|
5,000
-17.3%
22.44
USD 112,200
|
5,000
-17.3%
|
22.44
|
USD 112,200
|
|
|
2022-05-02 |
2022-04-28 |
S
Sale
|
Helsel Dave
SVP Global Operations and R&D
Officer
|
3,513
-13.3%
22.44
USD 78,832
|
3,513
-13.3%
|
22.44
|
USD 78,832
|
|
|
2022-04-13 |
2022-04-12 |
S
Sale
|
JOHNSON WESLEY
Non-Executive Director
|
1,299
-1.6%
23.26
USD 30,215
|
1,299
-1.6%
|
23.26
|
USD 30,215
|
|
|
2022-04-13 |
2022-04-11 |
S
Sale
|
JOHNSON WESLEY
Non-Executive Director
|
6,201
-7.2%
23.00
USD 142,623
|
6,201
-7.2%
|
23.00
|
USD 142,623
|
|
|
2022-01-12 |
2022-01-12 |
B
Purchase
|
Trowbridge Stephen A
EVP and CFO
Officer
|
1,000
+1.3%
22.64
USD 22,640
|
1,000
+1.3%
|
22.64
|
USD 22,640
|
|
|
2022-01-12 |
2022-01-11 |
B
Purchase
|
Clemmer James C
President and CEO
Executive Director
|
10,000
+2.6%
22.84
USD 228,400
|
10,000
+2.6%
|
22.84
|
USD 228,400
|
|
|
2021-10-21 |
2021-10-20 |
S
Sale
|
Helsel Dave
SVP Global Operations and R&D
Officer
|
3,494
-11.7%
27.97
USD 97,727
|
3,494
-11.7%
|
27.97
|
USD 97,727
|
|
|
2021-10-18 |
2021-10-15 |
S
Sale
|
Centea Scott
Sr. VP/GM, Global VIT
Officer
|
12,000
-20.6%
27.92
USD 335,040
|
12,000
-20.6%
|
27.92
|
USD 335,040
|
|
|
2021-10-06 |
2021-10-05 |
S
Sale
|
Campbell Chad Thomas
SVP/GM, Vascular Access
Officer
|
10,748
-25.3%
27.15
USD 291,808
|
10,748
-25.3%
|
27.15
|
USD 291,808
|
|
|
2021-04-15 |
2021-04-14 |
S
Sale
|
Helsel Dave
SVP Global Operations and R&D
Officer
|
3,500
-15.5%
23.93
USD 83,755
|
3,500
-15.5%
|
23.93
|
USD 83,755
|
|
|
2021-01-21 |
2021-01-20 |
S
Sale
|
JOHNSON WESLEY
Non-Executive Director
|
6,500
-7.7%
18.53
USD 120,445
|
6,500
-7.7%
|
18.53
|
USD 120,445
|
|
|
2020-08-12 |
2020-08-11 |
B
Purchase
|
Trowbridge Stephen A
EVP and CFO
Officer
|
1,013
+1.7%
9.38
USD 9,502
|
1,013
+1.7%
|
9.38
|
USD 9,502
|
|
|
2020-08-03 |
2020-07-31 |
B
Purchase
|
Clemmer James C
President and CEO
Executive Director
|
40,000
+13.2%
8.26
USD 330,400
|
40,000
+13.2%
|
8.26
|
USD 330,400
|
|
|
2019-10-28 |
2019-10-25 |
B
Purchase
|
Clemmer James C
President and CEO
Executive Director
|
15,000
+6.1%
14.19
USD 212,850
|
15,000
+6.1%
|
14.19
|
USD 212,850
|
|
|
2019-07-18 |
2019-07-16 |
S
Sale
|
Gould Kevin J
|
13,650
-19.8%
21.45
USD 292,793
|
13,650
-19.8%
|
21.45
|
USD 292,793
|
|
|
2018-11-08 |
2018-11-07 |
S
Sale
|
Greiner Michael
EVP and CFO
Officer
|
1,939
-8.6%
21.53
USD 41,747
|
1,939
-8.6%
|
21.53
|
USD 41,747
|
|
|
2017-11-17 |
2017-11-15 |
S
Sale
|
Richard Stark
SVP, GM - Oncology
|
27,409
-56.9%
16.29
USD 446,493
|
27,409
-56.9%
|
16.29
|
USD 446,493
|
|
|
2017-07-25 |
2017-07-24 |
B
Purchase
|
REED JAN STERN
Non-Executive Director
|
316
+inf%
16.00
USD 5,056
|
316
+inf%
|
16.00
|
USD 5,056
|
|
|
2017-07-21 |
2017-07-21 |
B
Purchase
|
Clemmer James C
President and CEO
Executive Director
|
5,000
+5.8%
15.79
USD 78,950
|
5,000
+5.8%
|
15.79
|
USD 78,950
|
|
|
2017-07-21 |
2017-07-21 |
B
Purchase
|
DONNELLY HOWARD W
Non-Executive Director
|
5,000
+11.7%
15.72
USD 78,600
|
5,000
+11.7%
|
15.72
|
USD 78,600
|
|
|
2017-07-21 |
2017-07-20 |
B
Purchase
|
Clemmer James C
President and CEO
Executive Director
|
20,000
+30.0%
15.64
USD 312,800
|
20,000
+30.0%
|
15.64
|
USD 312,800
|
|
|
2017-04-14 |
2017-04-12 |
S
Sale
|
Avista Capital Partners GP, LLC
Large shareholder
|
384,184
-50.2%
16.00
USD 6,146,944
|
384,184
-50.2%
|
16.00
|
USD 6,146,944
|
|
|
2017-04-14 |
2017-04-12 |
S
Sale
|
Avista Capital Partners GP, LLC
Large shareholder
|
508,869
-50.2%
16.00
USD 8,141,904
|
508,869
-50.2%
|
16.00
|
USD 8,141,904
|
|
|
2017-04-14 |
2017-04-12 |
S
Sale
|
Avista Capital Partners GP, LLC
Large shareholder
|
1,456,947
-50.2%
16.00
USD 23,311,152
|
1,456,947
-50.2%
|
16.00
|
USD 23,311,152
|
|
|
2017-04-14 |
2017-04-12 |
S
Sale
|
Burgstahler David F
Large shareholder
|
384,184
-50.2%
16.00
USD 6,146,944
|
384,184
-50.2%
|
16.00
|
USD 6,146,944
|
|
|
2017-04-14 |
2017-04-12 |
S
Sale
|
Burgstahler David F
Large shareholder
|
508,869
-50.2%
16.00
USD 8,141,904
|
508,869
-50.2%
|
16.00
|
USD 8,141,904
|
|
|
2017-04-14 |
2017-04-12 |
S
Sale
|
Burgstahler David F
Large shareholder
|
1,456,947
-50.2%
16.00
USD 23,311,152
|
1,456,947
-50.2%
|
16.00
|
USD 23,311,152
|
|
|
2016-11-22 |
2016-11-18 |
S
Sale
|
Avista Capital Partners GP, LLC
Large shareholder
|
541,349
-34.8%
15.68
USD 8,488,352
|
541,349
-34.8%
|
15.68
|
USD 8,488,352
|
|
|
2016-11-22 |
2016-11-18 |
S
Sale
|
Burgstahler David F
Non-Executive Director
Large shareholder
|
541,349
-34.8%
15.68
USD 8,488,352
|
541,349
-34.8%
|
15.68
|
USD 8,488,352
|
|
|
2016-11-22 |
2016-11-18 |
S
Sale
|
Avista Capital Partners GP, LLC
Large shareholder
|
1,549,945
-34.8%
15.68
USD 24,303,138
|
1,549,945
-34.8%
|
15.68
|
USD 24,303,138
|
|
|
2016-11-22 |
2016-11-18 |
S
Sale
|
Burgstahler David F
Non-Executive Director
Large shareholder
|
1,549,945
-34.8%
15.68
USD 24,303,138
|
1,549,945
-34.8%
|
15.68
|
USD 24,303,138
|
|
|
2016-08-05 |
2016-08-05 |
S
Sale
|
Burgstahler David F
Non-Executive Director
Large shareholder
|
487,214
-23.9%
14.62
USD 7,123,069
|
487,214
-23.9%
|
14.62
|
USD 7,123,069
|
|
|
2016-08-05 |
2016-08-05 |
S
Sale
|
Burgstahler David F
Non-Executive Director
Large shareholder
|
367,836
-23.9%
14.62
USD 5,377,762
|
367,836
-23.9%
|
14.62
|
USD 5,377,762
|
|
|
2016-08-05 |
2016-08-05 |
S
Sale
|
Avista Capital Partners GP, LLC
Large shareholder
|
478,214
-23.5%
14.62
USD 6,991,489
|
478,214
-23.5%
|
14.62
|
USD 6,991,489
|
|
|
2016-08-05 |
2016-08-05 |
S
Sale
|
Avista Capital Partners GP, LLC
Large shareholder
|
367,836
-23.9%
14.62
USD 5,377,762
|
367,836
-23.9%
|
14.62
|
USD 5,377,762
|
|
|
2016-08-05 |
2016-08-05 |
S
Sale
|
Burgstahler David F
Non-Executive Director
Large shareholder
|
1,394,950
-23.9%
14.62
USD 20,394,169
|
1,394,950
-23.9%
|
14.62
|
USD 20,394,169
|
|
|
2016-08-05 |
2016-08-05 |
S
Sale
|
Avista Capital Partners GP, LLC
Large shareholder
|
1,394,950
-23.9%
14.62
USD 20,394,169
|
1,394,950
-23.9%
|
14.62
|
USD 20,394,169
|
|
|
2016-05-09 |
2016-05-06 |
S
Sale
|
Greiner Charles R
VP - Global Franchise
Officer
|
3,508
-14.4%
12.31
USD 43,183
|
3,508
-14.4%
|
12.31
|
USD 43,183
|
|
|
2016-04-25 |
2016-04-25 |
S
Sale
|
Trowbridge Stephen A
SVP and General Counsel
Officer
|
2,440
-7.5%
12.18
USD 29,719
|
2,440
-7.5%
|
12.18
|
USD 29,719
|
|
|
2016-04-25 |
2016-04-21 |
S
Sale
|
Trowbridge Stephen A
SVP and General Counsel
Officer
|
10,500
-24.4%
12.33
USD 129,465
|
10,500
-24.4%
|
12.33
|
USD 129,465
|
|
|
2015-02-19 |
2015-02-13 |
S
Sale
|
Richard Stark
SVP, GM - Oncology
Officer
|
18,100
-38.7%
18.53
USD 335,393
|
18,100
-38.7%
|
18.53
|
USD 335,393
|
|
|
2014-10-21 |
2014-10-20 |
S
Sale
|
Greiner Charles R
VP - Global Franchise
Officer
|
3,298
-13.0%
15.63
USD 51,548
|
3,298
-13.0%
|
15.63
|
USD 51,548
|
|
|
2013-11-15 |
2013-11-14 |
S
Sale
|
Greiner Charles R
VP - Global Finance
Officer
|
4,373
-15.9%
15.46
USD 67,611
|
4,373
-15.9%
|
15.46
|
USD 67,611
|
|
|
2013-11-15 |
2013-11-13 |
S
Sale
|
Greiner Charles R
VP - Global Finance
Officer
|
2,392
-9.4%
15.40
USD 36,842
|
2,392
-9.4%
|
15.40
|
USD 36,842
|
|
|
2013-10-21 |
2013-10-18 |
B
Purchase
|
BUCCI VINCENT
Non-Executive Director
|
5,000
+6.1%
15.20
USD 75,990
|
5,000
+6.1%
|
15.20
|
USD 75,990
|
|
|
2013-10-21 |
2013-10-17 |
S
Sale
|
DONNELLY HOWARD W
Non-Executive Director
|
20,000
-55.8%
15.06
USD 301,200
|
20,000
-55.8%
|
15.06
|
USD 301,200
|
|
|
2013-07-23 |
2013-07-22 |
B
Purchase
|
Gould Kevin J
Non-Executive Director
|
2,700
+32.7%
12.00
USD 32,400
|
2,700
+32.7%
|
12.00
|
USD 32,400
|
|
|
2013-03-13 |
2013-03-12 |
B
Purchase
|
BUCCI VINCENT
Non-Executive Director
|
10,000
+333.3%
10.80
USD 108,000
|
10,000
+333.3%
|
10.80
|
USD 108,000
|
|
|
2013-03-13 |
2013-03-12 |
B
Purchase
|
BUCCI VINCENT
Non-Executive Director
|
35,000
+1166.7%
10.76
USD 376,600
|
35,000
+1166.7%
|
10.76
|
USD 376,600
|
|
|
2013-03-13 |
2013-03-12 |
B
Purchase
|
BUCCI VINCENT
Non-Executive Director
|
40,000
+103.4%
10.78
USD 431,200
|
40,000
+103.4%
|
10.78
|
USD 431,200
|
|
|
2013-03-12 |
2013-03-12 |
B
Purchase
|
Meteny Dennis S
Non-Executive Director
|
4,600
+26.5%
10.82
USD 49,772
|
4,600
+26.5%
|
10.82
|
USD 49,772
|
|
|
2013-02-15 |
2013-02-14 |
B
Purchase
|
BUCCI VINCENT
Non-Executive Director
|
2,000
+5.5%
12.17
USD 24,332
|
2,000
+5.5%
|
12.17
|
USD 24,332
|
|
|
2013-01-14 |
2013-01-11 |
B
Purchase
|
Gould Kevin J
Non-Executive Director
|
2,700
+48.6%
11.58
USD 31,277
|
2,700
+48.6%
|
11.58
|
USD 31,277
|
|
|
2012-11-13 |
2012-11-05 |
B
Purchase
|
GOLD JEFFREY
Non-Executive Director
|
1,000
+4.1%
10.56
USD 10,560
|
1,000
+4.1%
|
10.56
|
USD 10,560
|
|
|
2012-11-09 |
2012-11-05 |
S
Sale
|
Richard Stark
SVP, GM - Oncology
Officer
|
3,160
-10.9%
10.36
USD 32,738
|
3,160
-10.9%
|
10.36
|
USD 32,738
|
|
|
2012-07-18 |
2012-07-17 |
B
Purchase
|
DEVIVO JOSEPH
President and CEO
Executive Director
|
2,000
+5.6%
11.67
USD 23,340
|
2,000
+5.6%
|
11.67
|
USD 23,340
|
|
|
2012-05-17 |
2012-05-16 |
S
Sale
|
Richard Stark
SVP, GM - Oncology
Officer
|
2,080
-9.0%
12.42
USD 25,827
|
2,080
-9.0%
|
12.42
|
USD 25,827
|
|
|
2012-04-13 |
2012-04-12 |
B
Purchase
|
BUCCI VINCENT
Non-Executive Director
|
4,000
+inf%
11.82
USD 47,280
|
4,000
+inf%
|
11.82
|
USD 47,280
|
|
|
2012-04-12 |
2012-04-11 |
B
Purchase
|
Gould Kevin J
Non-Executive Director
|
2,700
+inf%
11.72
USD 31,636
|
2,700
+inf%
|
11.72
|
USD 31,636
|
|
|
2012-04-10 |
2012-04-10 |
B
Purchase
|
Kapusta Matthew C
SVP, Business Development
Officer
|
1,000
+6.7%
11.40
USD 11,397
|
1,000
+6.7%
|
11.40
|
USD 11,397
|
|
|
2012-04-10 |
2012-04-09 |
B
Purchase
|
BUCCI VINCENT
Non-Executive Director
|
2,000
+6.7%
11.80
USD 23,596
|
2,000
+6.7%
|
11.80
|
USD 23,596
|
|
|
2012-04-10 |
2012-04-09 |
B
Purchase
|
DEVIVO JOSEPH
President and CEO
Executive Director
|
5,000
+16.1%
11.82
USD 59,094
|
5,000
+16.1%
|
11.82
|
USD 59,094
|
|
|
2012-02-21 |
2012-02-21 |
B
Purchase
|
BUCCI VINCENT
Non-Executive Director
|
2,000
+7.2%
13.44
USD 26,878
|
2,000
+7.2%
|
13.44
|
USD 26,878
|
|
|
2012-02-15 |
2012-02-15 |
B
Purchase
|
BUCCI VINCENT
Non-Executive Director
|
2,000
+7.7%
13.25
USD 26,494
|
2,000
+7.7%
|
13.25
|
USD 26,494
|
|
|
2012-02-15 |
2012-02-13 |
B
Purchase
|
BUCCI VINCENT
Non-Executive Director
|
1,000
+4.0%
12.93
USD 12,927
|
1,000
+4.0%
|
12.93
|
USD 12,927
|
|
|
2012-02-13 |
2012-02-13 |
B
Purchase
|
DEVIVO JOSEPH
President and CEO
Executive Director
|
3,000
+10.7%
12.95
USD 38,850
|
3,000
+10.7%
|
12.95
|
USD 38,850
|
|
